|TAKURO ISODA||Last modified date：2021.07.02|
Assistant Professor / Department of Clinical Radiology / Department of Clinical Medicine / Faculty of Medical Sciences
|TAKURO ISODA||Last modified date：2021.07.02|
|1.||Takuro Isoda, Shingo Baba, Yasuhiro Maruoka, Yoshiyuki Kitamura, Masayuki Sasaki, Kousei Ishigami, 131I/18FDG Flip-Flop Phenomenon in the Bone Metastasis from Differentiated Thyroid Cancer, Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting, 2020.07.|
|2.||Takuro Isoda, Shingo Baba, Yoshiyuki Kitamura, Ryo Somehara, Masayuki Sasaki, Hiroshi Honda, Interval change in the degree of iodine uptake in lung metastasis from thyroid cancer between first and second radioiodine therapy; pulmonary uptake first emerges at the second radioiodine therapy in some patients, Society of Nuclear Medicine and Molecular Imaging 2019 Annual Meeting , 2019.06.|
|3.||Takuro Isoda, Shingo Baba, Yasuhiro Maruoka, Yoshiyuki Kitamura, Masayuki Sasaki, Masasmitsu Hatakenaka, Hiroshi Honda, Prediction of salivary gland disorder after radioiodine therapy with the evaluation of iodine uptake in salivary glands on iodine scintigraphy, SNMMI2016, 2016.06, Objectives: The impairment of salivary glands is one of the major complications after radioiodine therapy (RIT) for thyroid cancer. In this study, we investigated whether the disorder of salivary glands after RIT can be predicted with iodine uptake in salivary glands at RIT.
Methods: Forty patients who received the first radioiodine therapy for thyroid cancer from Jan. 2013 to Aug. 2014 and had the salivary gland scintigraphy before one year after the RIT were included (Age: 25–73 y.o., Median: 56.5 y.o., M : F = 14 : 26). All patients had total thyroidectomy. Nine patients received rhTSH injections before RIT and 31 patients had 4 weeks of thyroid hormone cessation. All patients had 2 weeks of iodine-free diet. The salivary gland scintigraphy with 99mTc- was performed just before and one year after the first RIT. The impairment of salivary gland was analyzed by comparing the salivary gland scintigraphy before and one year after RIT. Uptake of iodine-131 in salivary glands was evaluated with iodine scintigraphy performed 5 or 6 days after iodine-131 administration. The ratio of patients who showed the decreased uptake or the diminished response to stimulation of secretion on the salivary gland scintigraphy was compared between the patients with and without iodine uptake in the salivary glands. χ square test was used for statistical analysis. p < 0.05 was considered as statistically significant.
Results: In total, 22 out of 40 patients (55.0%) who received the RIT showed the impairment of salivary glands. Ten out of the 15 patients (66.7%) with iodine uptake in salivary gland showed the impairment of salivary glands one year after the RIT, while 8 out of 25 patients (32.0%) without iodine uptake in salivary glands did (p = 0.033).
Conclusions: The patients who showed iodine uptake on iodine scintigraphy at RIT had salivary glands disorder more frequently compared to those who did not..
|4.||磯田 拓郎, Impact of the patient age on flip-flop phenomenon in lung metastasis from thyroid cancer, Europian Congress of Radiology, 2015.03, FDG avid thyroid cancer lesions accumulate radioiodine with lower frequency, which is so called flip-flop phenomenon. The aim of this study was to analyze the impact of patient age to flip-flop phenomenon in the metastasized pulmonary lesions.
Methods: The cases of 75 patients who had radioiodine therapy for lung metastasis were studied retrospectively (age 17–73 yrs, median: 60 yrs; males : females, 22 : 53). We analyzed the relationship between the absence of iodine uptake and FDG avidity in the metastasized pulmonary lesions and compared the result between the two groups (age ≧ 60 yrs vs. age < 60 yrs).
Results: In younger patients (< 60 yrs), 7 out of 14 patients (50%) with FDG avid lung metastasis showed iodine uptake in the pulmonary lesion. On the other hand, 7 out of 30 patients (23.3%) with FDG avid lung metastasis showed pulmonary uptake in the older patients (≧ 60 yrs).
Conclusions: Our results show that the influence of FDG avidity to iodine uptake in the lung metastasis is varied depending on the patient age and younger patients with FDG avid lung metastasis still have the chance for a successful radioiodine therapy. Therefore, it is suggested that radioiodine therapy should be performed for the young patients even when their pulmonary lesions show FDG uptake.
|5.||Iodine-131 accumulation in bone metastasis from thyroid cancer; relationship with FDG uptake.|
|6.||磯田 拓郎, Evaluation of Diagnostic Performance of a Computer-Aided Diagnostic System, BONENAVI, on bone scintigraphy images, Annual Meeting 2015 of Society of Nuclear Medicine and Molecular Imaging, 2014.06, Objectives: BONENAVI is a computer aided diagnostic system on bone scintigraphies, which provides quantitative parameters such as artificial neural networks (ANN) and bone scan index (BSI); ANN and BSI are parameters related to the possibility and amount of bone metastases, respectively. In this study, we assessed the diagnostic performance of BONENAVI by comparing the accuracy in diagnosing bone metastases among segmented regions such as spine and ribs, and also analyzed the influence from the type of bone metastasis (osteolytic or osteoblastic) on the ANN value.
Methods: Fifty-three patients who undergone bone scintigraphy and were diagnosed with bone metastases were includes (Age: 33–87 y.o., Median: 69 y.o., M : F = 33 : 20). Bone metastases were diagnosed clinically using the following modalities; bone scintigraphy, CT, FDG-PET and MRI. Diagnostic performance of BONENAVI was evaluated on the basis of each segmented region such as skull, spine (cervical, thoracic and lumbar), clavicle, scapula, rib, sternum, humerus, pelvic bone, sacrum and femur by comparing ANN value and clinical diagnosis. The lesions of bone metastases were classified into 3 groups depending on the ratio of osteolytic and osteoblastic areas; osteolytic, osteoblastic and intermediate type, then ANN value of the lesions was compared among the 3 groups using Mann-Whitney U test for statistical analysis.
Results; Diagnostic performance of BONENAVI was high in thoracic spine, humerus, rib and femur but low in skull, cervical spine, scapula and sternum when comparing the accuracy. Osteoblastic lesions showed significantly higher ANN value than osteolytic lesions (Median; 0.703 vs. 0.974, p = 0.029) and 3 out of 15 osteolytic lesions were misdiagnosed.
Conclusion: Diagnostic performance of BONENAVI varied depending on the regions where bone metastases occurred. Osteolytic lesions were sometimes misdiagnosed. We need to take account of these tendencies when diagnosing bone metastases with BONENAVI.